Relief Therapeutics shares have soared 38,000% in 2020

LONDON — Swiss biotech firm Relief Therapeutics has seen its share price climb by 38,000% so far this year, as it develops a drug focused on respiratory failure arising from severe Covid-19.

Last week, the company, along with U.S. partner NeuroRx, met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration in their ongoing phase 2b/3 trial of RLF-100, which is a patented version of aviptadil.

Aviptadil is a synthetic formulation of a naturally occurring peptide called Vasoactive Intestinal Polypeptide…